Medicus Pharma Proposes SkinJect SPAC Combination at $135 Million Valuation

What happened

Medicus Pharma announced a non-binding proposal to combine SkinJect with an undisclosed SPAC, valuing SkinJect at $135 million before financing. The proposed deal includes concurrent equity financing for a planned Gorlin syndrome study and potential NDA preparation, and would create a separately listed company. It remains subject to agreements, financing, approvals, due diligence and other conditions.

Proposed

Global impact / market context

If completed, the financing could fund SkinJect’s planned study and work toward a possible NDA, a formal request for FDA approval to sell a medicine. A separate listing could give SkinJect its own shares, while Medicus intends to retain majority economic and voting ownership.

Analyst inference

The proposal connects SkinJect’s research funding needs with a potential public listing, but neither financing nor the transaction is final. The FDA has issued a “Study May Proceed” letter for the planned Phase 2b study; that permits the study to proceed, not proof of treatment effectiveness or approval.

Confirmed

What to watch

1. Whether Medicus and the undisclosed SPAC reach definitive agreements, and whether the required financing, approvals and due diligence are completed; each remains a condition to the proposed transaction. Confirmed
2. Whether the proposed equity financing is secured and supports the planned SKNJCT-005 study in Gorlin syndrome and potential NDA preparation, as the proposal describes. Confirmed
3. Whether the planned study produces results that support NDA preparation, which could affect SkinJect’s regulatory path and the rationale for a separate listing. Analyst inference

Evidence

• Original source link unavailable